{
    "id": 18266,
    "fullName": "MTOR P2213S",
    "impact": "missense",
    "proteinEffect": "gain of function",
    "geneVariantDescriptions": [
        {
            "description": "MTOR P2213S lies within the PI3K/PI4K domain of the Mtor protein (UniProt.org). P2213S results in constitutive activation of Mtor signaling and increased phosphorylation of p70S6K, 4Ebp1 and Akt in cell culture (PMID: 26490311).",
            "references": [
                {
                    "id": 4623,
                    "pubMedId": 26490311,
                    "title": "Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26490311"
                },
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 2475,
        "geneSymbol": "MTOR",
        "terms": [
            "MTOR",
            "FRAP",
            "FRAP1",
            "FRAP2",
            "RAFT1",
            "RAPT1",
            "SKS"
        ]
    },
    "variant": "P2213S",
    "createDate": "02/18/2016",
    "updateDate": "02/18/2016",
    "referenceTranscriptCoordinates": {
        "id": 145367,
        "transcript": "NM_004958",
        "gDna": "chr1:g.11124523G>A",
        "cDna": "c.6637C>T",
        "protein": "p.P2213S",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 4602,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human cell lines overexpressing MTOR P2213S demonstrated reduced sensitivity to Alpelisib (BYL719)-induced growth inhibition in culture (PMID: 26490311).",
            "molecularProfile": {
                "id": 18604,
                "profileName": "MTOR P2213S"
            },
            "therapy": {
                "id": 691,
                "therapyName": "Alpelisib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4623,
                    "pubMedId": 26490311,
                    "title": "Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26490311"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4592,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, AZD5363 inhibited proliferation of transformed human cell lines overexpressing MTOR P2213S in culture (PMID: 26490311).",
            "molecularProfile": {
                "id": 18604,
                "profileName": "MTOR P2213S"
            },
            "therapy": {
                "id": 655,
                "therapyName": "Capivasertib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4623,
                    "pubMedId": 26490311,
                    "title": "Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26490311"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 4605,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, transformed human cell lines overexpressing MTOR P2213S demonstrated reduced sensitivity to Afinitor (everolimus)-induced growth inhibition in culture (PMID: 26490311).",
            "molecularProfile": {
                "id": 18604,
                "profileName": "MTOR P2213S"
            },
            "therapy": {
                "id": 735,
                "therapyName": "Everolimus",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 4623,
                    "pubMedId": 26490311,
                    "title": "Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26490311"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 4598,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, LY294002 inhibited proliferation of transformed human cell lines overexpressing MTOR P2213S in culture (PMID: 26490311).",
            "molecularProfile": {
                "id": 18604,
                "profileName": "MTOR P2213S"
            },
            "therapy": {
                "id": 1062,
                "therapyName": "LY294002",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 4623,
                    "pubMedId": 26490311,
                    "title": "Analysis of mTOR Gene Aberrations in Melanoma Patients and Evaluation of Their Sensitivity to PI3K-AKT-mTOR Pathway Inhibitors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26490311"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 18604,
            "profileName": "MTOR P2213S",
            "profileTreatmentApproaches": [
                {
                    "id": 7848,
                    "name": "mTORC1 Inhibitor",
                    "profileName": "MTOR P2213S"
                },
                {
                    "id": 7849,
                    "name": "mTORC2 Inhibitor",
                    "profileName": "MTOR P2213S"
                },
                {
                    "id": 7847,
                    "name": "mTOR Inhibitor",
                    "profileName": "MTOR P2213S"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 145368,
            "transcript": "XM_005263438",
            "gDna": "chr1:g.11124523G>A",
            "cDna": "c.6637C>T",
            "protein": "p.P2213S",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        },
        {
            "id": 145367,
            "transcript": "NM_004958",
            "gDna": "chr1:g.11124523G>A",
            "cDna": "c.6637C>T",
            "protein": "p.P2213S",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}